Joshua R. Dunetz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joshua R. Dunetz has a total of 147 co-authors. Here are the top co-authors by number of shared publications:
- Javier Magano
Chemical Research and Development, Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340, United States
4 shared publications Martin A. Berliner
3 shared publications- Rick L&Period; Danheiser&Ast;1<&Sol;A<&Sol;Span<&Sol;Sup
MIT, Dept Chem, Cambridge, MA 02139 USA
3 shared publications Amanda L. Kohnen
2 shared publicationsAnn S. Wright
Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States
2 shared publicationsBrian P. Boscoe
Neuroscience and Pain Medicinal Chemistry, ‡Pharmacokinetics, Dynamics, and Metabolism, and §Neuroscience and Pain Research Unit, Pfizer Inc. , Cambridge, Massachusetts 02139, United States
2 shared publications
Latest Publications
- 13 September 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (18) , 7764-7780
Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates
We previously observed a cutaneous type IV immune response in nonhuman primates (NHP) with the mGlu5 negative allosteric modulator (NAM) 7. To determine if this adverse event was chemotype- or mechanism-based, we evaluated a distinct series of mGlu5 NAMs. Increasing the sp3 character of high-throughput screening hit 40 afforded a novel morpholinopyrimidone mGlu5 NAM series. Its prototype, (R)-6-neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894, 8), possessed favorable properties and a predicted low clinical dose (2 mg twice daily). Compound 8 did not show any evidence of immune activation in a mouse drug allergy model. Additionally, plasma samples from toxicology studies confirmed that 8 did not form any reactive metabolites. However, 8 caused the identical microscopic skin lesions in NHPs found with 7, albeit with lower severity. Holistically, this work supports the hypothesis that this unique toxicity may be mechanism-based although additional work is required to confirm this and determine clinical relevance.
- 13 September 2017
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 60 (18) , 7764-7780
Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates
We previously observed a cutaneous type IV immune response in nonhuman primates (NHP) with the mGlu5 negative allosteric modulator (NAM) 7. To determine if this adverse event was chemotype- or mechanism-based, we evaluated a distinct series of mGlu5 NAMs. Increasing the sp3 character of high-throughput screening hit 40 afforded a novel morpholinopyrimidone mGlu5 NAM series. Its prototype, (R)-6-neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894, 8), possessed favorable properties and a predicted low clinical dose (2 mg twice daily). Compound 8 did not show any evidence of immune activation in a mouse drug allergy model. Additionally, plasma samples from toxicology studies confirmed that 8 did not form any reactive metabolites. However, 8 caused the identical microscopic skin lesions in NHPs found with 7, albeit with lower severity. Holistically, this work supports the hypothesis that this unique toxicity may be mechanism-based although additional work is required to confirm this and determine clinical relevance.
- Top Cited Papers
- 5 February 2016
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 20 (2) , 140-177
Large-Scale Applications of Amide Coupling Reagents for the Synthesis of Pharmaceuticals
- 5 February 2016
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 20 (2) , 140-177
Top Cited PapersLarge-Scale Applications of Amide Coupling Reagents for the Synthesis of Pharmaceuticals
- 16 October 2015
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 19 (10) , 1325-1326
Spotlight on Non-Precious Metal Catalysis
- 16 October 2015
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 19 (10) , 1325-1326
Spotlight on Non-Precious Metal Catalysis
- 13 October 2014
- Published by Royal Society of Chemistry (RSC) in Catalysis Series
- p. 697-778
CHAPTER 15. Recent Large-Scale Applications of Transition Metal-Catalyzed Couplings for the Synthesis of Pharmaceuticals
A review on recent applications of transition metal-catalyzed couplings on a large scale (>100 mmol) in the pharmaceutical industry is presented. Carbon–carbon, carbon–nitrogen and carbon–sulfur bond formation are discussed and relevant examples of each type of coupling are described with synthetic schemes that show the cross-coupling step and also the structure of the final active pharmaceutical ingredient (API). Special emphasis is placed on the practical aspects of these chemistries to make them amenable for scale-up. In addition, important issues such as metal removal to comply with stringent regulatory specifications are discussed.
- 13 October 2014
- Published by Royal Society of Chemistry (RSC) in Catalysis Series
- p. 697-778
CHAPTER 15. Recent Large-Scale Applications of Transition Metal-Catalyzed Couplings for the Synthesis of Pharmaceuticals
A review on recent applications of transition metal-catalyzed couplings on a large scale (>100 mmol) in the pharmaceutical industry is presented. Carbon–carbon, carbon–nitrogen and carbon–sulfur bond formation are discussed and relevant examples of each type of coupling are described with synthetic schemes that show the cross-coupling step and also the structure of the final active pharmaceutical ingredient (API). Special emphasis is placed on the practical aspects of these chemistries to make them amenable for scale-up. In addition, important issues such as metal removal to comply with stringent regulatory specifications are discussed.
- 18 August 2014
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 18 (9) , 1145-1152
Rapid Enabling of Negishi Couplings for a Pair of mGluR5 Negative Allosteric Modulators
- 18 August 2014
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 18 (9) , 1145-1152
Rapid Enabling of Negishi Couplings for a Pair of mGluR5 Negative Allosteric Modulators
- 22 January 2014
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (3) , 861-877
Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator
A novel series of pyrazolopyrazines is herein disclosed as mGluR5 negative allosteric modulators (NAMs). Starting from a high-throughput screen (HTS) hit (1), a systematic structure–activity relationship (SAR) study was conducted with a specific focus on balancing pharmacological potency with physicochemical and pharmacokinetic (PK) properties. This effort led to the discovery of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine (PF470, 14) as a highly potent, selective, and orally bioavailable mGluR5 NAM. Compound 14 demonstrated robust efficacy in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-rendered Parkinsonian nonhuman primate model of l-DOPA-induced dyskinesia (PD-LID). However, the progression of 14 to the clinic was terminated because of a potentially mechanism-mediated finding consistent with a delayed-type immune-mediated type IV hypersensitivity in a 90-day NHP regulatory toxicology study.
- 22 January 2014
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (3) , 861-877
Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator
A novel series of pyrazolopyrazines is herein disclosed as mGluR5 negative allosteric modulators (NAMs). Starting from a high-throughput screen (HTS) hit (1), a systematic structure–activity relationship (SAR) study was conducted with a specific focus on balancing pharmacological potency with physicochemical and pharmacokinetic (PK) properties. This effort led to the discovery of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo[3,4-b]pyrazine (PF470, 14) as a highly potent, selective, and orally bioavailable mGluR5 NAM. Compound 14 demonstrated robust efficacy in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-rendered Parkinsonian nonhuman primate model of l-DOPA-induced dyskinesia (PD-LID). However, the progression of 14 to the clinic was terminated because of a potentially mechanism-mediated finding consistent with a delayed-type immune-mediated type IV hypersensitivity in a 90-day NHP regulatory toxicology study.
- 26 March 2013
- Published by Elsevier in Journal of Chromatography A
- Vol. 1293, 150-158
Chiral separation of amides using supercritical fluid chromatography
- 26 March 2013
- Published by Elsevier in Journal of Chromatography A
- Vol. 1293, 150-158
Chiral separation of amides using supercritical fluid chromatography
- 24 September 2012
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 16 (10) , 1635-1645
Multikilogram Synthesis of a Hepatoselective Glucokinase Activator
- 24 September 2012
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 16 (10) , 1635-1645
Multikilogram Synthesis of a Hepatoselective Glucokinase Activator
- Top Cited Papers
- 5 April 2012
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 16 (6) , 1156-1184
Large-Scale Carbonyl Reductions in the Pharmaceutical Industry
- 5 April 2012
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 16 (6) , 1156-1184
Top Cited PapersLarge-Scale Carbonyl Reductions in the Pharmaceutical Industry
- 29 August 2011
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 13 (19) , 5048-5051
General and Scalable Amide Bond Formation with Epimerization-Prone Substrates Using T3P and Pyridine
The mild combination of T3P (n-propanephosphonic acid anhydride) and pyridine has been developed for low-epimerization amide bond formation and implemented for the synthesis of a key intermediate to a glucokinase activator. This robust method is general for the coupling of various racemization-prone acid substrates and amines, including relatively non-nucleophilic anilines, and provides amides in high yields with very low epimerization. With easy reaction setup and product isolation, this protocol offers several practical and experimental benefits.
- 29 August 2011
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 13 (19) , 5048-5051
General and Scalable Amide Bond Formation with Epimerization-Prone Substrates Using T3P and Pyridine
The mild combination of T3P (n-propanephosphonic acid anhydride) and pyridine has been developed for low-epimerization amide bond formation and implemented for the synthesis of a key intermediate to a glucokinase activator. This robust method is general for the coupling of various racemization-prone acid substrates and amines, including relatively non-nucleophilic anilines, and provides amides in high yields with very low epimerization. With easy reaction setup and product isolation, this protocol offers several practical and experimental benefits.